When scientific excellence meets bold capital, life-changing projects can emerge. Taveren Therapeutics is a perfect example—a Czech biotech spin-off that could bring a completely new approach to cancer treatment.
An Investment That Supports Hope
The law firm Ambit (formerly Mavericks) had the honour of representing Dr. Zuzana Kečkéšová, founder of the biotechnology company Taveren Therapeutics, in securing an investment of nearly CZK 100 million from bpd partners a.s. and B3 Holding. This investment represents another step in the long-term support of Dr. Kečkéšová's research.
Legal advice for this key transaction was provided by Ambit's M&A team, led by Tomáš Ditrych and Ondřej Lukeš, who ensured that the entire process ran smoothly and that the interests of the founder of Taveren Therapeutics were protected.
A Fascinating Scientific Question with the Potential to Transform Medicine
Dr. Kečkéšová's interest was piqued by the fact that certain human tissues—such as the heart, muscles, or cartilage—almost never develop cancer. This led her to question how these tissues protect themselves and whether this protective mechanism could be transferred to cancerous tumours to suppress their effect.
From MIT to ÚOCHB to Her Own Biotechnology Company
Dr. Zuzana Kečkéšová has been engaged in this research for many years, beginning with her postgraduate work at the renowned Massachusetts Institute of Technology (MIT). Her work focuses on a unique strategy to strengthen the body's natural ability to defend itself against malignant tumours. The research continues at the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (ÚOCHB).
The research team is currently working with three therapeutic compounds capable of reactivating one of these tumour suppression mechanisms.
A Unique Partnership Model
This form of partnership is unique in that the commercial sector supports promising ideas and research even before a patent is filed. Such investments accelerate research that ultimately leads to new insights into how the human body functions—or even more effective treatments for serious diseases.
The investment will be used to complete the key preclinical phase. If the project is successful, the company will submit an application to begin clinical trials involving human patients.
Projects like Taveren Therapeutics confirm that Czech pharmaceutical research ranks among the world's best. With the necessary capital and a dedicated team, we may witness something extraordinary—Czech science helping to tackle even the most difficult diseases.
Congratulations to Dr. Zuzana Kečkéšová, bpd partners and B3 Holding on this exceptional investment in the future of healthcare technologies and biotechnology.